After 510(k), Can Buyers Actually Find You?

A 510(k) decision can appear in the FDA database before the manufacturer's own website gives a buyer a usable way to discover, understand, verify, and inquire about the device.

That gap is easy to underestimate. Regulatory teams quite rightly concentrate on the submission. Product teams concentrate on verification, validation, labeling, and launch readiness. Commercial teams prepare distributors, events, training, and target accounts. The public website is often treated as a final communications task: update the product menu, write a press release, and move on.

But the FDA record and the market do not move on the same clock. The clearance is public. A distributor can search it. A competitor can search it. A clinician, investor, hospital stakeholder, journalist, or prospective partner can arrive at the applicant's name with no context beyond a K-number and device name. What they find next becomes part of the commercial experience.

To see how often that experience is ready, VayoMed Research analyzed the FDA's 2026 510(k) data through June 27 and audited the public web surfaces of 60 non-U.S. companies that appeared to receive a first 510(k) under their current applicant name. We resolved official company domains, then checked 471 public HTML pages for observable signals: the cleared product, FDA/510(k) language, K-numbers, current evidence or content, technical discovery signals, and a route to contact the company.

The result is not a story about companies having no websites. It is more specific—and more actionable:

• 56 of 60 companies could be connected to an official domain.
• 49 of those domains returned public HTML during the audit.
• 46 of the 49 reachable sites exposed a contact or inquiry route.
• Yet the newly cleared product term was found in the bounded audit for only 27 of the 60 companies.
• FDA or 510(k) language was found for 32.
• A K-number was found for only three.

In other words, the conversion endpoint often existed. The product-specific path leading a buyer to that endpoint was much less consistent.

That is the clearance-to-commercialization gap this report examines. It does not measure revenue, sales coverage, distributor relationships, traffic, or offline launch execution. It asks a narrower question: when a buyer starts with the public record or a product need, has the company built enough public evidence for that buyer to keep moving?

First, use the right regulatory language

Before discussing growth, it is worth correcting a common commercial shortcut. A device that reaches the market through the 510(k) pathway is FDA cleared, not FDA approved.

The distinction is not stylistic. The FDA describes the 510(k) process as a premarket notification used to demonstrate substantial equivalence to a legally marketed predicate device. The agency's own training material states that FDA clears 510(k)s and that it is inappropriate to refer to a 510(k) device as “FDA approved” 1. Premarket approval, or PMA, is a different pathway.

Registration and listing are different again. The FDA notes that registering a medical-device establishment or listing a device does not mean the agency has approved the establishment, facility, or listed device 2.

This creates three separate public facts that commercial content must not blur:

1. Establishment registration and device listing identify regulated establishments and devices in scope. They are not an endorsement.
2. 510(k) clearance reflects the agency's substantial-equivalence decision for the device and intended use described in the submission.
3. PMA approval is a different premarket review route and supports the word “approved” in a way a 510(k) decision does not.

The practical rule is simple: build every product claim from the cleared device's actual decision, indications for use, labeling, and approved internal claim matrix. Do not let a copywriter “improve” regulatory language. Do not turn registration into approval. Do not generalize one cleared configuration to an entire product family without review.

Correct language does more than reduce risk. It makes the public evidence more useful. A buyer who sees the exact trade name, applicant, K-number, decision date, intended-use wording, and a link to the FDA record can verify that the page and public record describe the same product. That clarity is a commercial asset.

The 2026 post-clearance cohort is already substantial

The FDA makes releasable 510(k) records available for download and says the download files are replaced monthly, usually around the fifth day of the month 3. We analyzed K-number decisions in the file through June 27, 2026. We excluded DEN-prefixed De Novo decisions that were present in the source export because this report is specifically about 510(k)s.

The file contained 1,647 K-number decisions in 2026 through that date. Of those, 869 decision rows listed a non-U.S. applicant country. Those rows represented 650 raw applicant names and 645 applicant entities after conservative name normalization.

Most of those applicants were not prolific 2026 filers: 511 of the 645 had one clearance in the period. Under an exact normalized-name history check, 201 applicant names had no earlier K-number record. Of that group, 186 had one 2026 clearance.

That last figure is useful, but it needs a careful label. We call these apparent first-time applicants, not proven first-time corporate entrants. An established company can file through a new subsidiary. An acquisition can change the applicant. A transliteration, punctuation difference, or legal-name change can split one corporate history into multiple database names. We removed obvious incumbents from the 60-company website sample after manual review, but the aggregate 201 remains a name-based signal.

Even with that limitation, the data reveals a recurring commercial moment. In less than six months, hundreds of non-U.S. companies had a fresh U.S. regulatory decision. For some, it was the first visible decision under that applicant name. Each event created a new set of public questions:

• What exactly is the product?
• Who is the legal manufacturer, and which brand sells it?
• Is it available in the United States now?
• What was cleared, for which use, and under what configuration?
• What evidence supports evaluation?
• Who handles clinical, distributor, commercial, or partnership inquiries?

The companies were not concentrated in one geography. China accounted for 310 of the 869 non-U.S. decision rows, followed by South Korea with 86 and Germany with 59. Israel, Switzerland, France, Japan, Taiwan, Canada, and Italy also had meaningful activity.

Nor was this one narrow device segment. Radiology led with 152 decision rows, followed by the FDA category “General, Plastic Surgery” with 107, Cardiovascular with 93, Orthopedic with 86, and Dental with 72. The cohort also included gastroenterology/urology, physical medicine, neurology, obstetrics and gynecology, general-hospital devices, anesthesiology, and other specialties.

The commercial-readiness problem is therefore not limited to one country, business model, or product type. It appears wherever a regulatory milestone outpaces the public system that explains and distributes it.

Identity fragments before a buyer reaches the website

A buyer may encounter a legal applicant name in the FDA database, a different brand on the product, a parent-company name on LinkedIn, another entity in EUDAMED, and a shortened corporate name on the website. Each variation may be valid. Together, however, they create an entity-resolution task for both people and machines.

We tested that problem across public regulatory datasets. Of the 645 normalized non-U.S. applicant names, 460 matched exactly to an FDA Registration & Listing name, 354 to an FDA UDI company name, 451 to an EUDAMED actor, and 134 to an EUDAMED certificate actor. Twenty matched a 2025 ClinicalTrials.gov lead sponsor and 11 matched a 2026 lead sponsor. Overall, 550 of 645—85.3%—matched at least one of those secondary sources.

These are not compliance rates. Exact matching misses legitimate relationships, and a match does not prove that every record is current or belongs to the same corporate group. The result instead illustrates a discovery problem: even structured regulatory data does not automatically produce one coherent public identity.

The company must do that work deliberately. A strong public identity layer connects:

• the legal applicant name;
• the commercial company and parent, where relevant;
• the product brand and cleared trade name;
• the official domain and regional domains;
• the K-number and FDA record;
• the company LinkedIn page and authorized spokespersons; and
• contact paths for buyers, distributors, media, clinical questions, and other stakeholders.

This does not mean every page should be crowded with legal names. It means the connections should be explicit somewhere canonical and machine-readable. A footer legal identity, an About-page explanation, consistent Organization and Product structured data, and a well-constructed regulatory section can reduce ambiguity without damaging the brand experience.

What the 60-company audit found

We built a structured sample of 60 companies from the 186 apparent first-time applicant names with one 2026 clearance. To prevent one geography from defining the result, the sample included 22 companies from China and Taiwan, 18 from Europe, six from South Korea and Japan, six from Canada/Australia/New Zealand, four from Israel, and four from other regions. Within each region, the selection rotated across FDA medical specialties.

We then resolved domains using applicant emails and URLs in FDA summaries, official product pages, and exact company/product searches. A regulatory consultant, agent, distributor, or third-party database page was not accepted as the manufacturer's official domain.

Four domains could not be resolved with sufficient confidence. Seven more did not return public HTML within the audit protocol. This left 49 reachable sites. For those sites, we checked the homepage and up to 11 same-domain pages prioritized around products, solutions, FDA/510(k), resources, news, evidence, and contact. The bounded audit covered 471 pages on July 21, 2026.

The full-sample result shows a steep drop between general web presence and product-specific regulatory evidence:

1. The domain usually existed

We resolved an official domain for 56 of the 60 companies. That is encouraging. The first problem is not universal absence from the web.

But legal-entity-to-domain resolution was not always obvious. In several cases, the most visible search results were regulatory databases, company directories, consultants, distributors, or similarly named businesses. Four companies had no official domain we could identify confidently. A buyer may be able to find those companies through private networks, trade shows, marketplaces, or local search engines; our result only says the public English-language trail was not clear enough for confident resolution.

This is the first readiness test: when the applicant name becomes public, can a buyer reliably connect it to the official company and brand?

2. Contact was easier to find than the newly cleared product

Of the 49 reachable sites, 46 exposed a contact path. That could be a contact page, form, email, telephone link, demo request, distributor inquiry, or similar route.

The cleared product term appeared in the bounded page set for 27 sites—55.1% of reachable sites and 45% of the full sample. This is a conservative string- detection test, not a judgment on the page's quality. A renamed product, localized page, blocked page, or JavaScript-only content can produce a false negative. Yet that limitation is commercially meaningful: if a crawler cannot retrieve the product from the obvious public paths, a buyer or search system may also face friction.

The mismatch points to a common website architecture problem. The generic contact destination exists, but the product story that should qualify and motivate the inquiry is absent, difficult to locate, or disconnected from the cleared trade name.

A product-specific route should not make a buyer reconstruct the story from a PDF and a generic corporate homepage. At minimum, it should answer:

• What is this device and which buyer problem does it address?
• Who is it intended for, using reviewed language?
• Which configuration or model is described?
• What regulatory decision applies?
• Which clinical, technical, workflow, or economic evidence is available?
• In which markets is it offered, and through whom?
• What is the appropriate next step?

3. FDA language was more common than a verifiable identifier

FDA or 510(k) language appeared somewhere in the bounded page set for 32 of the 49 reachable websites. A K-number appeared for only three.

This does not mean every medical-device product page should lead with a regulatory identifier. It does mean a buyer should have a dependable way to verify a clearance claim. The FDA maintains a searchable releasable 510(k) database 4, and the decision number is the simplest bridge between a marketing page and that source record.

Without the bridge, “FDA cleared” can remain ambiguous. Does the statement refer to this product, an earlier model, a component, an accessory, another company in the group, or a different configuration? The more complex the portfolio, the more useful specificity becomes.

A practical pattern is to put concise, reviewed regulatory information on the product page and link to a fuller regulatory/evidence page. The fuller page can hold the K-number, decision date, exact cleared trade name, applicable indications, downloadable labeling or instructions where appropriate, and the official FDA record. The product page stays readable while the evidence remains verifiable.

4. Technical foundations were present, but uneven

Among the 49 reachable sites, 44 had mobile viewport metadata, 43 returned with valid HTTPS in the audit, 34 had a useful-length homepage title, 34 had a meta description, 34 exposed a sitemap, and 32 used a canonical link.

These checks are intentionally basic. A viewport tag does not prove that forms, tables, menus, consent banners, and product documents work well on a small screen. A sitemap does not prove that the right product URL is indexed. A meta description is not a ranking guarantee.

They matter because they remove avoidable discovery friction. Google recommends descriptive, concise titles; useful page descriptions; crawlable links; and sitemaps where they help discovery 5. Google also uses the mobile version of a site's content for indexing and recommends responsive design, with equivalent primary content and metadata across mobile and desktop 6. Its technical requirements make the baseline clear: pages need to be accessible to Google, return a successful HTTP status, and contain indexable content 7.

The commercial implication is not “do SEO after clearance.” It is “make the cleared product part of the site's actual information architecture.” The page must be linked, crawlable, mobile-readable, internally connected to relevant evidence, and included in the publishing/distribution system. Otherwise, a perfectly written page can remain an orphan.

5. A content surface often existed; current product evidence did not always follow

Forty-one reachable sites exposed some form of content or evidence surface: news, resources, publications, articles, or clinical material. Twenty-seven had an explicit 2025 or 2026 date on such a surface. Twenty-seven exposed a LinkedIn link in the retrieved HTML.

This suggests that many companies already have pieces of a publishing system. The missing step is orchestration. A corporate news archive may be current while the new product is absent. A product page may exist while the evidence lives in an unlinked PDF library. A LinkedIn page may announce the clearance but point to a homepage that does not mention it. A press release may be syndicated but not preserved in the company's own newsroom. Each asset exists; the buyer journey does not.

Commercial readiness is a connected evidence system

It is tempting to convert the audit into a checklist of page fixes: add the K-number, update the title, create a contact form, submit the sitemap. Those actions help, but isolated repairs do not create a compounding growth system.

The deeper operating requirement is a shared truth layer and a coordinated publishing loop.

The truth layer

The truth layer is the controlled set of facts from which every public asset is built. For a newly cleared device, it can include:

• cleared trade name and model/configuration;
• legal applicant and commercial brand relationship;
• K-number, decision date, pathway, product code, and classification;
• indications for use and carefully reviewed claims;
• technical specifications and workflow boundaries;
• supporting studies, standards, testing summaries, labeling, and instructions;
• market availability and distributor status; and
• approved terminology for audiences and use cases.

Regulatory, medical, legal, product, and commercial owners should agree on this layer before content scales. The point is not to make every asset sound the same. It is to ensure that a product page, article, press release, executive post, distributor deck, and AI/search answer all rest on the same controlled facts.

The canonical page

The canonical product page is the public source of truth for discovery. It should be written for the intended buyer, but detailed enough to disambiguate the device. It should link outward to authoritative sources and inward to useful evidence. It should have one durable URL rather than a campaign URL that disappears after launch.

The best page is not the longest. It is the page that lets a qualified visitor answer four questions quickly:

1. Is this relevant to my use case?
2. Can I understand and verify the claim?
3. Is there enough evidence to continue evaluation?
4. Can I reach the right person or next step?

The evidence cluster

One product page cannot responsibly answer every question. The next layer is a small cluster of source-grounded pages addressing real evaluation needs:

• a category or clinical-workflow explainer;
• a technical comparison framed around requirements, not unsupported superiority;
• an evidence or study summary;
• implementation, integration, or training content;
• a regulatory explainer that uses the correct pathway language;
• a distributor or market-availability page; and
• answers to high-intent questions from buyers and clinical stakeholders.

Each page should have a reason to exist beyond adding keywords. It should answer a distinct question, cite primary evidence, connect back to the canonical product page, and offer a relevant next step.

The distribution layer

Publishing is not distribution. The clearance and its supporting evidence can be adapted into a sequence across the company newsroom, LinkedIn, email, authorized distributor channels, trade media, and PR distribution. The sequence should create multiple paths back to the same verified source rather than multiple inconsistent versions of the claim.

This is where coordination creates leverage:

regulatory source → controlled claim → canonical page → evidence content → LinkedIn and PR → third-party citations → search/AI discovery → qualified inquiry

No link in that chain guarantees the next. Content does not guarantee ranking. PR distribution does not guarantee editorial coverage. Visibility does not guarantee leads or revenue. But a coherent system gives the market more accurate and durable opportunities to discover and evaluate the company than a single launch announcement.

A 90-day post-clearance build sequence

The right sequence depends on product complexity, claim-review capacity, channel strategy, and what already exists. The following 90-day model is a practical baseline for a small non-U.S. team building an English-language commercial surface.

Days 0–30: establish the truth layer

The first month is about accuracy, identity, and a durable destination.

1. Run an identity audit. Map the applicant, parent, brand, trade name, domain, regional entities, and social profiles. Decide how those relationships will be explained publicly.

2. Build the claim matrix. Start with the decision letter, 510(k) summary, indications for use, labeling, and approved internal materials. Assign owners for regulatory, medical, legal, product, and commercial review. Flag language that must not be generalized.

3. Publish or rebuild the canonical product page. Use a durable URL, clear product/category language, reviewed intended-use wording, relevant models, the K-number, an official source link, evidence links, and a specific inquiry route.

4. Fix the launch path. Add the product to navigation and relevant category pages. Verify mobile behavior, status codes, canonical tags, page title, description, structured data, internal links, and sitemap inclusion. Test forms on mobile and route inquiries to an accountable owner.

Decision gate: Can an unfamiliar but qualified buyer identify the company, understand the device, verify the clearance, and take the next step without leaving the public path to reconstruct the story?

Days 31–60: build the evidence cluster

The second month turns one announcement into a set of useful answers.

1. Interview commercial and clinical-facing teams. Collect the recurring questions from distributors, clinicians, procurement, integration partners, and field teams. Separate education questions from product claims.

2. Prioritize three to five high-value assets. Choose topics based on buyer friction, evidence availability, and strategic category relevance—not search volume alone. A strong first cluster often includes a workflow explainer, an evidence summary, an implementation/integration page, a regulatory clarification, and an audience-specific FAQ.

3. Create a proof library. Centralize public studies, posters, testing, certifications, instructions, demonstrations, publications, and approved media. Record provenance and last-review dates. Make each asset usable by the website, sales team, LinkedIn, PR, and partners.

4. Connect the cluster. Every evidence page should link to the canonical product page and to adjacent questions where useful. The product page should surface the strongest proof rather than hiding it in a download center.

Decision gate: Can a buyer move from “what is it?” to “why is it relevant?” and “what evidence should I review?” through a coherent set of source-grounded pages?

Days 61–90: distribute, measure, and establish cadence

The third month turns the evidence base into an operating rhythm.

1. Build a clearance narrative sequence. The decision itself is one story. Follow it with the problem, mechanism or workflow, evidence, implementation, and market-availability stories. Adapt each for the channel while preserving the same claim base.

2. Coordinate owned and earned distribution. Publish to the company newsroom, LinkedIn, and relevant email or partner channels. Use a press release when the milestone and distribution objective justify it. Preserve the final release and coverage links on the company's domain.

3. Measure discovery and evaluation—not vanity alone. Establish search and AI query baselines, indexed-page coverage, branded and product query trends, engaged visits to product/evidence pages, document use, form completion, and inquiry quality. Treat dynamic search and AI answers as observations, not guaranteed permanent rankings.

4. Set the next-quarter backlog. Use real buyer questions, sales-call friction, regulatory milestones, evidence releases, competitor activity, and query data to plan the next content. Keep review capacity visible so volume does not outrun governance.

Decision gate: Is the company repeatedly publishing and distributing useful, reviewed evidence—and learning which questions and paths attract qualified evaluation?

A 12-point self-audit for your newly cleared device

The following test can be completed without an enterprise marketing stack. Ask someone who was not involved in the submission or website project to perform it on both desktop and mobile.

Identity and verification

• Can they connect the FDA applicant name to the official company and brand?
• Can they find the cleared trade name or an explicit explanation of any new commercial name?
• Can they find the K-number and reach the official FDA record?
• Does the page say “cleared,” not “approved,” for a 510(k) device?

Product understanding

• Can they identify the intended audience, use case, and relevant model without relying on vague “innovative solution” language?
• Are the intended-use and benefit statements aligned with reviewed claims?
• Can they find primary or appropriately contextualized supporting evidence?
• Can they understand availability, training, integration, or distributor next steps relevant to the product?

Discovery and action

• Is the product reachable through navigation and internal links, not only a press release or PDF?
• Does the page work on mobile, return public HTML, and expose useful titles, descriptions, canonicals, and sitemap paths?
• Do recent articles, evidence, LinkedIn, or newsroom updates lead back to the canonical product source?
• Does the inquiry path name a meaningful next step and reach an accountable owner?

If the answer is “no” to several questions, the remedy is not necessarily a complete rebrand. Start by repairing the truth layer and canonical path. Then build the evidence and distribution cadence around them.

Clearance opens the market; readiness opens the path

The FDA clearance is a major achievement. The data in this report does not diminish it. It shows why the next operating phase needs to begin immediately.

Across our 60-company sample, official domains and contact routes were common. The weaker link was the path from a public regulatory event to a discoverable, specific, verifiable product story. Only 27 companies exposed the cleared product term in the bounded audit. Only three exposed a K-number. Those figures may include false negatives, but the direction is clear enough to act on: commercial readiness is not created by the clearance record itself.

It is built through consistent identity, a canonical product page, controlled claims, source-grounded evidence, technical discoverability, coordinated distribution, and a relevant conversion route. When those parts share one operating system, each regulatory and evidence milestone can strengthen the public surface instead of becoming another isolated announcement.

VayoMed builds and runs that system for life-sciences companies as a Done-for-You Global Growth Engine: website build and operations, LinkedIn, domain management, source-grounded content and GEO, PR distribution, and AI visibility managed as one $24,000/year annual subscription under a 12-month agreement. For a company approaching clearance or discovering that its public launch trail is incomplete, the first useful conversation is not about producing more content. It is about identifying the broken link between regulatory truth and qualified discovery. The service does not promise rankings, inquiries, distributors, or revenue; it provides the coordinated operating system and delivery cadence.

Methodology and limitations

VayoMed Research analyzed the FDA downloadable 510(k) file through June 27,

1. Only K-number records were included. Non-U.S. status used the applicant

country field. Applicant names were normalized for an exact historical-name comparison; “apparent first-time” means no earlier K-number under that normalized name and does not prove first clearance across a parent group, subsidiary, acquisition, or prior legal identity.

The 60-company sample was drawn from apparent first-time non-U.S. applicant names with one 2026 clearance, after excluding obvious established incumbents and continuity cases. Regional quotas and specialty round-robin selection were used for diagnostic diversity; the sample is not probability-weighted.

Domains were resolved manually from FDA summaries, official product/company pages, and exact applicant/product searches. On July 21, 2026, the audit checked the homepage and up to 11 prioritized same-domain HTML pages for each reachable site. Unresolved domains and unreachable sites were retained as separate outcomes. Product detection used one curated trade-name/model term per company.

The audit is a one-day public-web snapshot from one network location. Temporary outages, geoblocking, robots rules, JavaScript rendering, localized content, renamed products, or unlinked pages may create false negatives. Signal presence does not verify claim accuracy or page quality. The study does not measure traffic, rankings, AI recommendations, inquiries, distributors, revenue, or commercial performance and does not establish causation. Company-level audit results remain private; only aggregate results are published.

Sources

1. U.S. Food and Drug Administration, “The 510(k) Program” transcript. FDA explains substantial equivalence and the distinction between clearance and approval. Read the FDA transcript.
2. U.S. Food and Drug Administration, “Is It Really ‘FDA Approved’?” Includes the distinction among approval, clearance, and registration/listing. Read the FDA consumer update.
3. U.S. Food and Drug Administration, “Downloadable 510(k) Files.” The FDA states that releasable 510(k) files are available for download and generally replaced monthly. Open the FDA download page.
4. U.S. Food and Drug Administration, “Search for Releasable 510(k) Database.” Open the FDA search page.
5. Google Search Central, “SEO Starter Guide.” Guidance on descriptive titles, descriptions, crawlable links, and sitemaps. Read the SEO Starter Guide.
6. Google Search Central, “Mobile-first indexing best practices.” Guidance on mobile content, metadata, and responsive design. Read the mobile-first guidance.
7. Google Search Central, “Technical requirements.” Baseline requirements for Google Search eligibility and indexable content. Read the technical requirements.